Stockreport

Longeveron Reports Year-End 2023 Results and Provides Corporate Update [Yahoo! Finance]

Longeveron Inc. - Class A Common stock  (LGVN) 
PDF ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Long-term Survival Data from ELPIS 1 Trial Prese [Read more]